Advertisement

Search Results for "Memantine Epar"

21:59 EDT 19th May 2013 | BioPortfolio

Original Source: Human medicines European Public Assessment Report (EPAR): Ebixa, memantine, Revision: 20, Authorised

Matching Channels

Alzheimer's Disease

Of all the types of Dementia, Alzheimer's disease is the most common, affecting around 465,000 people in the UK. Neurons in the brain die, becuase  'plaques' and 'tangles'...

Matching News

Matching PubMed Articles

Use of memantine for the treatment of dementia.

The term 'dementia' encompasses a number of neurodegenerative diseases of which Alzheimer's disease (AD) is the most common. Prior to 2003, cholinesterase inhibitors, such as donezepil, were the only...

A trans-disciplinary overview of case reports of thunderstorm-related asthma outbreaks and relapse.

Memantine in dementia: a review of the current evidence.

Introduction: As the world's population ages, the incidence of Alzheimer's disease (AD) is projected to double every 20 years. Understanding the pathogenesis of AD and developing effective treatments...

High-performance liquid chromatographic determination of memantine hydrochloride in rat plasma using sensitive fluorometric derivatization.

In this study, we investigated a simple, sensitive and reliable liquid chromatography-fluorescence detection method for the determination of memantine hydrochloride in rat plasma which was based on de...

Key Binding Interactions for Memantine in the NMDA Receptor.

Memantine (Namenda) is prescribed as a treatment for moderate to severe Alzheimer's Disease. Memantine functions by blocking the NMDA receptor, but the key binding interactions between drug and recept...

Search Whole site using Google

Loading
Search BioPortfolio:
Advertisement
Advertisement
Advertisement Advertisement